Document is current
Any future updates will be listed below
-
Authors
Galeano Niño, Jorge Luis
Wu, Hanrui
LaCourse, Kaitlyn D.
Srinivasan, Harini
Fitzgibbon, Matthew https://orcid.org/0009-0008-7557-0442
Minot, Samuel S.
Sather, Cassie
Johnston, Christopher D.
Bullman, Susan https://orcid.org/0000-0002-7713-0810
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R00 CA229984-03)
Cancer Research Institute (CRI4208)
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA015704, P30 CA015704, P30 CA015704)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01 DE027850)
- License Information
-
More Information
Article History
Received: 21 December 2022
Accepted: 11 July 2023
First Online: 3 October 2023
Competing interests
: S.B. has consulted for GlaxoSmithKline and BiomX. C.D.J. has consulted for Series Therapeutics and Azitra. S.B. is an inventor on US Patent Application no: PCT/US2018/042966, submitted by the Broad Institute and Dana-Farber Cancer Institute, that covers targeting of <i>Fusobacterium</i> for treatment of CRC cancer.
